Advertisement

Narcolepsy

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hublin C.
        • Kaprio J.
        • Partinene M.
        • et al.
        The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort.
        Ann Neurol. 1994; 35: 709-716
        • Mignot E.
        Genetic and familial aspects of narcolepsy.
        Neurology. 1998; 50: S16-S22
        • American Academy of Sleep Medicine
        ICSD-2-International classification of sleep disorders. Diagnostic and coding manual. 2nd edition. American Academy of Sleep Medicine, Westchester (IL)2005
        • Beusterien K.M.
        • Rogers A.E.
        • Walsleben J.A.
        • et al.
        Health-related quality of life effects of modafinil for treatment of narcolepsy.
        Sleep. 1999; 22: 757-765
        • Mignot E.
        • Lammers G.J.
        • Ripley B.
        • et al.
        The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
        Arch Neurol. 2002; 59: 1553-1562
        • Nishino S.
        • Kanbayashi T.
        Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
        Sleep Med Rev. 2005; 9: 269-310
        • Nishino S.
        • Mignot E.
        Pharmacological aspects of human and canine narcolepsy.
        Prog Neurobiol. 1997; 52: 27-78
        • Honda Y.
        Clinical features of narcolepsy: Japanese experience.
        in: Honda Y. Juji T. HLA in narcolepsy. Springer-Verlag, New York1988: 24-57
        • Gelb M.
        • Guilleminault C.
        • Kraemer H.
        • et al.
        Stability of cataplexy over several months-information for the design of therapeutic trials.
        Sleep. 1994; 17: 265-273
        • Overeem S.
        • Mignot E.
        • van Dijk J.G.
        • et al.
        Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.
        J Clin Neurophysiol. 2001; 18: 78-105
        • Group USXMS
        A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.
        Sleep. 2002; 25: 42-49
        • Nishino S.
        • Ripley B.
        • Overeem S.
        • et al.
        Hypocretin (orexin) deficiency in human narcolepsy.
        Lancet. 2000; 355: 39-40
        • Nishino S.
        • Kanbayashi T.
        • Fujiki N.
        • et al.
        CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies.
        Neurology. 2003; 61: 823-825
        • Overeem S.
        • Dalmau J.
        • Bataller L.
        • et al.
        Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis.
        Neurology. 2004; 62: 138-140
        • Alaila S.L.
        Life effects of narcolepsy: measures of negative impact, social support and psychological well-being.
        in: Goswanmi M. Pollak C.P. Cohen F.L. Loss, grief and care: psychosocial aspects of narcolepsy, vol. 5. Haworth Press, New York1992: 1-22
        • Black J.E.
        • Brooks S.N.
        • Nishino S.
        Narcolepsy and syndromes of primary excessive daytime somnolence.
        Semin Neurol. 2004; 24: 271-282
        • Smolik P.
        • Roth B.
        Kleine-Levin syndrome ethiopathogenesis and treatment.
        Acta Univ Carol Med Monogr. 1988; 128: 5-94
        • Billiard M.
        Kleine Levin syndrome.
        in: Krieger M.H. Roth T. Dement W.C. Principles and practice of sleep medicine. WB Saunders, Philadelphia1989: 377-378
        • Dement W.
        • Rechtschaffen A.
        • Gulevich G.
        The nature of the narcoleptic sleep attack.
        Neurology. 1966; 16: 18-33
        • Broughton R.
        • Valley V.
        • Aguirre M.
        • et al.
        Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective.
        Sleep. 1986; 9: 205-215
        • Guilleminault C.
        • Wilson R.A.
        • Dement W.C.
        A study on cataplexy.
        Arch Neurol. 1974; 31: 255-261
        • Nishino S.
        • Riehl J.
        • Hong J.
        • et al.
        Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans.
        Neurosci Res. 2000; 38: 437-446
        • Bishop C.
        • Rosenthal L.
        • Helmus T.
        • et al.
        The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness.
        Sleep. 1996; 19: 727-730
        • Aldrich M.S.
        • Chervin R.D.
        • Malow B.A.
        Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.
        Sleep. 1997; 20: 620-629
        • Fukuda K.
        • Miyasita A.
        • Inugami M.
        • et al.
        High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan.
        Sleep. 1987; 10: 279-286
        • Ohayon M.M.
        • Priest R.G.
        • Caulet M.
        • et al.
        Hypnagogic and hypnopompic hallucinations: pathological phenomena?.
        Br J Psychiatry. 1996; 169: 459-467
        • Juji T.
        • Satake M.
        • Honda Y.
        • et al.
        HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive.
        Tissue Antigens. 1984; 24: 316-319
        • Mignot E.
        • Hayduk R.
        • Black J.
        • et al.
        HLA class II studies in 509 narcoleptic patients.
        Sleep Res. 1997; 26: 433
        • Mignot E.
        • Guilleminault C.
        • Grumet F.C.
        • et al.
        Is narcolepsy an autoimmune disease?.
        in: Smirne S. Francesci M. Ferini-Strambi L. Proceedings of the Third Milano International Symposium, September 18–19 Sleep, Hormones, and the Immune System. Masson, Milan1992: 29-38
        • Billiard M.
        • Laaberki M.F.
        • Reygrobellet C.
        • et al.
        Elevated antibodies to streptococcal antigens in narcoleptic subjects.
        Sleep Res. 1989; 18: 201
        • Montplaisir J.
        • Poirier G.
        • Lapierre O.
        • et al.
        Streptococcal antibodies in narcolepsy and idiopathic hypersomnia.
        Sleep Res. 1989; 18: 271
        • Frederickson S.
        • Carlander B.
        • Billiard M.
        • et al.
        CSF immune variable in patients with narcolepsy.
        Acta Neurol Scand. 1990; 81: 253-254
        • Matsuki K.
        • Juji T.
        • Honda Y.
        Immunological features of narcolepsy in Japan.
        in: Honda Y. Juji T. HLA in narcolepsy. Springer-Verlag, New York1988: 150-157
        • Black III, J.L.
        • Krahn L.E.
        • Pankratz V.S.
        • et al.
        Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602.
        Sleep. 2002; 25: 719-723
        • Black III, J.L.
        • Silber M.H.
        • Krahn L.E.
        • et al.
        Studies of humoral immunity to preprohypocretin in human leukocyte antigen DQB1*0602-positive narcoleptic subjects with cataplexy.
        Biol Psychiatry. 2005; 58: 504-509
        • Mignot E.
        • Wang C.
        • Rattazzi C.
        • et al.
        Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment.
        Proc Natl Acad Sci U S A. 1991; 88: 3475-3478
        • Chemelli R.M.
        • Willie J.T.
        • Sinton C.M.
        • et al.
        Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
        Cell. 1999; 98: 437-451
        • Lin L.
        • Faraco J.
        • Li R.
        • et al.
        The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
        Cell. 1999; 98: 365-376
        • Peyron C.
        • Faraco J.
        • Rogers W.
        • et al.
        A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
        Nat Med. 2000; 6: 991-997
        • Nishino S.
        • Ripley B.
        • Overeem S.
        • et al.
        Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy.
        Ann Neurol. 2001; 50: 381-388
        • Krahn L.E.
        • Pankratz V.S.
        • Oliver L.
        • et al.
        Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.
        Sleep. 2002; 25: 733-736
        • Kanbayashi T.
        • Inoue Y.
        • Chiba S.
        • et al.
        CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.
        J Sleep Res. 2002; 11: 91-93
        • Thannickal T.C.
        • Moore R.Y.
        • Nienhuis R.
        • et al.
        Reduced number of hypocretin neurons in human narcolepsy.
        Neuron. 2000; 27: 469-474
        • Ripley B.
        • Fujiki N.
        • Okura M.
        • et al.
        Hypocretin levels in sporadic and familial cases of canine narcolepsy.
        Neurobiol Dis. 2001; 8: 525-534
        • De Lecea L.
        • Kilduff T.S.
        • Peyron C.
        • et al.
        The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.
        Proc Natl Acad Sci U S A. 1998; 95: 322-327
        • Sakurai T.
        • Amemiya A.
        • Ishii M.
        • et al.
        Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.
        Cell. 1998; 92: 573-585
        • Peyron C.
        • Tighe D.K.
        • van den Pol A.N.
        • et al.
        Neurons containing hypocretin (orexin) project to multiple neuronal systems.
        J Neurosci. 1998; 18: 9996-10015
        • Willie J.T.
        • Chemelli R.M.
        • Sinton C.M.
        • et al.
        To eat or to sleep? Orexin in the regulation of feeding and wakefulness.
        Annu Rev Neurosci. 2001; 24: 429-458
        • Taheri S.
        • Zeitzer J.M.
        • Mignot E.
        The role of hypocretins (orexins) in sleep regulation and narcolepsy.
        Annu Rev Neurosci. 2002; 25: 283-313
        • Nishino S.
        • Fujiki N.
        • Ripley B.
        • et al.
        Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
        Neurosci Lett. 2001; 313: 125-128
        • Huang Z.L.
        • Qu W.M.
        • Li W.D.
        • et al.
        Arousal effect of orexin A depends on activation of the histaminergic system.
        Proc Natl Acad Sci U S A. 2001; 98: 9965-9970
        • Yamanaka A.
        • Tsujino N.
        • Funahashi H.
        • et al.
        Orexins activate histaminergic neurons via the orexin 2 receptor.
        Biochem Biophys Res Commun. 2002; 290: 1237-1245
        • Eriksson K.S.
        • Sergeeva O.
        • Brown R.E.
        • et al.
        Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.
        J Neurosci. 2001; 21: 9273-9279
        • Nishino S.
        • Sakurai E.
        • Nevisimalova S.
        • et al.
        CSF histamine content is decreased in hypocretin-deficient human narcolepsy.
        Sleep. 2002; 25: A476
        • Shiba T.
        • Fujiki N.
        • Wisor J.
        • et al.
        Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice.
        Sleep. 2004; 27: A241
        • Fujiki N.
        • Yoshida Y.
        • Ripley B.
        • et al.
        Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation.
        Neuroreport. 2001; 12: 993-997
        • Yoshida Y.
        • Fujiki N.
        • Nakajima T.
        • et al.
        Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities.
        Eur J Neurosci. 2001; 14: 1075-1081
        • Zeitzer J.M.
        • Buckmaster C.L.
        • Parker K.J.
        • et al.
        Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness.
        J Neurosci. 2003; 23: 3555-3560
        • Mileykovskiy B.Y.
        • Kiyashchenko L.I.
        • Siegel J.M.
        Behavioral correlates of activity in identified hypocretin/orexin neurons.
        Neuron. 2005; 46: 787-798
        • Lee M.G.
        • Hassani O.K.
        • Jones B.E.
        Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle.
        J Neurosci. 2005; 25: 6716-6720
        • Aston-Jones G.
        • Chen S.
        • Zhu Y.
        • et al.
        A neural circuit for circadian regulation of arousal.
        Nat Neurosci. 2001; 4: 732-738
        • Wu M.F.
        • John J.
        • Maidment N.
        • et al.
        Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement.
        Am J Physiol Regul Integr Comp Physiol. 2002; 283: R1079-R1086
        • Roehrs T.
        • Zorick F.
        • Wittig R.
        • et al.
        Alerting effects of naps in patients with narcolepsy.
        Sleep. 1986; 9: 194-199
        • Thorpy M.J.
        • Goswami M.
        Treatment of narcolepsy.
        in: Thorpy M.J. Handbook of sleep disorders. Marcel Dekker, New York1990: 235-258
        • Mullington J.
        • Broughton R.
        Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy.
        Sleep. 1993; 16: 444-456
        • Rogers A.E.
        Problems and coping strategies identified by narcoleptic patients.
        J Neurosurg Nurs. 1984; 16: 326-334
        • American Narcolepsy Association
        Stimulant medication survey.
        The Eye Opener. 1992; : 1-3
        • Mitler M.M.
        • Aldrich M.S.
        • Koob G.F.
        • et al.
        Narcolepsy and its treatment with stimulants.
        Sleep. 1994; 17: 352-371
        • Lammers G.J.
        • Arends J.
        • Declerck A.C.
        • et al.
        Gamma-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study.
        Sleep. 1993; 16: 216-220
        • Scrima L.
        • Hartman P.G.
        • Johnson F.H.
        • et al.
        Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
        Biol Psychiatry. 1989; 26: 331-343
        • Nishino S.
        • Okura M.
        • Mignot E.
        Narcolepsy: genetic predisposition and neuropharmacological mechanisms.
        Sleep Med Rev. 2000; 4: 57-99
        • Mignot E.
        Pathophysiology of narcolepsy.
        in: Kryger M.H. Roth T. Dement W.C. Principles and practice of sleep medicine. WB Saunders, Philadelphia2000: 663-675
        • Nishino S.
        • Mao J.
        • Sampathkumaran R.
        • et al.
        Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.
        Sleep Research Online. 1998; 1 (Available at:) (Accessed December 24, 2005): 49-61
        • Wisor J.P.
        • Nishino S.
        • Sora I.
        • et al.
        Dopaminergic role in stimulant-induced wakefulness.
        J Neurosci. 2001; 21: 1787-1794
        • Babcock D.A.
        • Narver E.L.
        • Dement W.C.
        • et al.
        Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs.
        Pharmacol Biochem Behav. 1976; 5: 599-602
        • Foutz A.S.
        • Delashaw J.B.
        • Guilleminault C.
        • et al.
        Monoaminergic mechanisms and experimental cataplexy.
        Ann Neurol. 1981; 10: 369-376
        • Kiyashchenko L.I.
        • Mileykovskiy B.Y.
        • Lai Y.Y.
        • et al.
        Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area.
        J Neurophysiol. 2001; 85: 2008-2016
        • Nambu T.
        • Sakurai T.
        • Mizukami K.
        • et al.
        Distribution of orexin neurons in the adult rat brain.
        Brain Res. 1999; 827: 243-260
        • Hagan J.J.
        • Leslie R.A.
        • Patel S.
        • et al.
        Orexin A activates locus coeruleus cell firing and increases arousal in the rat.
        Proc Natl Acad Sci U S A. 1999; 96: 10911-10916
        • Horvath T.L.
        • Peyron C.
        • Diano S.
        • et al.
        Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system.
        J Comp Neurol. 1999; 415: 145-159
        • Fujiki N.
        • Ripley B.
        • Yoshida Y.
        • et al.
        Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog.
        Sleep. 2003; 6: 953-959
        • Kanbayashi T.
        • Yano T.
        • Ishiguro H.
        • et al.
        Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons.
        Sleep. 2002; 25: 337-339
        • Kubota H.
        • Kanbayashi T.
        • Tanabe Y.
        • et al.
        A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid.
        J Child Neurol. 2002; 17: 537-539
        • Hara J.
        • Beuckmann C.T.
        • Nambu T.
        • et al.
        Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.
        Neuron. 2001; 30: 345-354
        • Nishino S.
        The hypocretin/orexin system in health and disease.
        Biol Psychiatry. 2003; 54: 87-95